26th Apr 2016 09:27
LONDON (Alliance News) - Midatech Pharma PLC on Tuesday said it has received positive data from trials of its Q-Octreotide treatment for acromegaly and carcinoid syndrome.
The pilot pre-clinical study on the treatment confirmed the systemic release of Midatech's Q-Octreotide compared favourably to Sandostatin LAR Depot, the market leader made by Swiss drugmaker Novartis AG.
"Q-Octreotide is one of the most advanced of our in-house cancer treatments. Whilst preparing the programme for clinical development, the existing use of Octreotide gives us confidence that this programme can be progressed quickly," said Midatech Chief Executive Jim Phillips.
Midatech shares were up 1.1% to 183.95 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
MTPH.L